红醇及其类似物作为抗癌化合物:当前的机制性见解和结构-活性关系关系
Parteek Prasher1, Rabab Fatima1, Mousmee Sharma2
1Department of Chemistry, University of Petroleum & Energy Studies, Energy Acres, Dehradun, 248007, India.
红,一个来自马格诺利亚树的基,通过准细胞信号和转移,显示出强大的抗癌作用. 它的高生物可用性使其成为新型癌症化疗的有希望的候选者.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 灵是一种植物性多,具有显著的生物活性,包括抗癌性质.
- 红醇是来自马格诺利亚物种的酸盐,具有独特的物理化学特性,有助于其生物活性和生物可用性.
- 目前的癌症化疗药物经常面临生物可用性挑战,突出了对新药的需求.
研究的目的:
- 为了审查Honokiol的抗癌性质.
- 探索霍诺基奥尔抗癌效应背后的机制.
- 讨论Honokiol作为化疗剂的潜力.
主要方法:
- 文献综述关于香草生物活动的研究.
- 对Honokiol的物理化学特性和生物可用性的分析.
- 检查霍诺基奥尔对癌细胞信号通路,细胞周期和转移的作用.
主要成果:
- 红醇通过各种机制表现出抗癌作用,包括调节瘤信号通路.
- 它可以阻止细胞循环并抑制上皮层-介质细胞过渡,这是癌症转移的关键过程.
- 香的疏水性有助于穿越生理障碍,导致其高生物可用性.
结论:
- 霍诺基奥尔由于其多方面的作用机制,显示出显著的抗致癌潜力.
- 其有利的药理动力学特征将其定位为开发新型抗癌药物的有希望的候选者.
- 对霍诺基奥尔的进一步研究可能会导致改进的癌症化疗药物,提高生物可用性.
更多相关视频
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Local Anesthetics: Chemistry and Structure-Activity Relationship
Drugs that Stabilize Microtubules
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
